Equities

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,918.50
  • Today's Change38.00 / 2.02%
  • Shares traded504.02k
  • 1 Year change+17.59%
  • Beta0.4123
Data delayed at least 20 minutes, as of Mar 28 2024 18:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.

  • Revenue in GBP (TTM)2.27bn
  • Net income in GBP150.34m
  • Incorporated2005
  • Employees8.97k
  • Location
    Hikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
  • Phone+44 207 399 2760
  • Fax+44 207 399 2761
  • Websitehttps://www.hikma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Camurus AB128.00m32.17m2.24bn204.0069.5219.4167.4017.497.497.4930.1126.841.071.177.29--26.85-1.1333.67-1.4192.8790.0525.13-1.634.13--0.0162--79.52103.39676.63--14.06--
Indivior PLC864.85m1.58m2.32bn1.05k1,234.84--112.702.68-0.0375-0.03756.000.000.58721.454.61822,880.300.10741.320.28592.6282.9883.690.1832.680.859--1.000.0021.311.6996.00--5.27--
Virbac SA1.04bn102.33m2.45bn5.40k23.973.1817.282.3714.1214.12143.10106.420.87941.307.09224,710.408.597.2611.7010.3965.1965.809.768.981.25--0.15596.3414.317.137.78--6.98--
ALK-Abello A/S554.17m55.83m2.89bn2.82k59.316.1732.355.212.092.0920.9020.100.74021.326.111,708,215.007.463.509.424.3762.9160.6610.075.071.1835.050.14680.006.9410.6045.07--16.32--
Dottikon ES Holding AG296.08m75.43m2.90bn694.0037.993.8830.939.816.246.2424.4961.100.31350.63395.39498,861.307.997.489.588.4867.5878.9425.4822.351.65101.250.1062--26.8015.0947.9427.7030.78--
Siegfried Holding AG1.11bn98.09m3.59bn3.93k34.534.6021.113.2226.2826.28298.23197.490.69582.273.14323,288.606.176.517.677.9825.2023.248.869.061.397.930.346815.263.419.87-28.1618.3417.956.72
Krka d.d. Novo Mesto1.55bn268.93m3.64bn11.78k12.771.8510.032.3510.1410.1458.3670.020.66271.353.96153,343.9011.5112.6413.7515.1256.8457.2917.3718.712.5419.990.0055--5.186.28-13.5812.458.35--
Laboratorios Farmaceuticos ROVI SA710.57m145.91m3.73bn2.11k25.177.7522.775.253.203.2015.5810.410.98831.045.13392,946.0020.2918.9028.8825.5859.3559.8220.5320.130.8575--0.107533.601.4422.30-14.6956.9315.8469.11
Richter Gedeon Vegyeszeti Gyar Nyrt1.75bn344.66m3.75bn12.17k10.801.508.172.14857.81857.794,349.056,173.080.59311.714.08--11.8311.6413.3913.2864.7558.1819.9518.933.127.490.015939.700.299312.57-6.0535.0615.5933.38
Hikma Pharmaceuticals Plc2.27bn150.34m4.17bn8.97k27.802.3911.691.830.67650.676510.237.870.62841.763.67253,693.804.208.195.7211.3048.9450.296.6813.770.90297.680.350336.7114.226.731.06-7.597.974.54
Orion Oyj1.02bn185.71m4.17bn3.63k22.285.4418.464.091.551.558.496.340.80881.575.56327,588.1014.7219.4718.0324.1655.3059.3818.2020.711.7594.790.183591.83-11.264.01-37.971.8911.821.55
DiaSorin SpA-85.66bn-85.66bn4.26bn3.28k--------------------------13.14--14.79--67.40--23.33------23.899.9816.38-22.5311.4921.765.29
Grifols SA5.65bn50.81m4.36bn23.74k92.040.96688.180.77230.09010.09019.808.580.30681.239.86277,627.000.84082.391.063.0437.8440.262.747.541.291.560.5593--8.718.00-71.52-36.98-0.8127--
Zealand Pharma A/S39.38m-80.84m4.90bn253.00--24.98--124.49-12.57-12.576.0127.280.19484.16289.881,354,889.00-39.99-42.74-46.30-50.2487.3996.13-205.30-464.666.23--0.0696--229.6555.2727.12--42.53--
BACHEM HOLDING AG505.38m97.92m5.55bn2.01k56.404.8040.3710.981.501.507.7317.610.37651.233.33287,794.607.298.858.1710.2830.6531.6319.3819.743.0429.800.000355.378.5715.3711.1019.1250.887.78
Data as of Mar 28 2024. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX

Institutional shareholders

25.50%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202311.56m5.23%
JPMorgan International Bank Ltd.as of 08 Feb 202410.75m4.86%
Capital Research & Management Co. (World Investors)as of 08 Feb 20247.55m3.41%
BlackRock Advisors (UK) Ltd.as of 31 Dec 20236.15m2.78%
Mawer Investment Management Ltd.as of 30 Jun 20234.38m1.98%
The Vanguard Group, Inc.as of 08 Feb 20243.71m1.68%
Norges Bank Investment Managementas of 08 Feb 20243.60m1.63%
Threadneedle Asset Management Ltd.as of 31 Dec 20233.53m1.60%
Royal London Asset Management Ltd.as of 08 Feb 20242.63m1.19%
Polar Capital LLPas of 31 Jan 20242.53m1.14%
More ▼
Data from 31 Dec 2023 - 08 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.